Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 14/20 | 0.50 |
| ▸ | CA1 | P00915 | 13/20 | 0.50 |
| ▸ | CA12 | O43570 | 7/20 | 0.50 |
| ▸ | CA9 | Q16790 | 7/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27991145 | 0.90 | CA2 (0.52) | CA2CA1CA12CA9MEN1 | |
| SCHEMBL1238863 | 0.87 | MEN1 (0.57) | CA2CA1CA12CA9MEN1 | |
| SCHEMBL28299166 | 0.84 | CNR2 (0.47) | CA2CA1CNR2KCNH3KDM4E | |
| SCHEMBL2482925 | 0.83 | CNR2 (0.48) | CA2CA1CA12CA9CNR2 | |
| Sulfanilamide SCHEMBL1955933 | 0.78 | CA2 (0.47) | CA2CA1CA12CA9CNR2 | |
| SCHEMBL1700398 | 0.77 | BRD4 (0.48) | CA2CA1CA12CA9CNR2 | |
| SCHEMBL1956619 | 0.77 | CA2 (0.55) | CA2MEN1KMT2AMAPK1 | |
| SCHEMBL17090036 | 0.77 | CA1 (0.44) | CA2CA1CA12CA9MEN1 | |
| SCHEMBL1700047 | 0.76 | CA1 (0.51) | CA2CA1CA12CA9CNR2 | |
| SCHEMBL1700346 | 0.76 | CA2 (0.51) | CA2CA1CA12CA9CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109966294-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维爱尔兰无限公司 | 2019-07-05 | — | — | CN | disclosed |
| CN-109897038-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维爱尔兰无限公司 | 2019-06-18 | — | — | CN | disclosed |